GB201602413D0 - Method - Google Patents

Method

Info

Publication number
GB201602413D0
GB201602413D0 GBGB1602413.5A GB201602413A GB201602413D0 GB 201602413 D0 GB201602413 D0 GB 201602413D0 GB 201602413 A GB201602413 A GB 201602413A GB 201602413 D0 GB201602413 D0 GB 201602413D0
Authority
GB
United Kingdom
Prior art keywords
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1602413.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NASCIENT Ltd
Original Assignee
NASCIENT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NASCIENT Ltd filed Critical NASCIENT Ltd
Priority to GBGB1602413.5A priority Critical patent/GB201602413D0/en
Publication of GB201602413D0 publication Critical patent/GB201602413D0/en
Application status is Ceased legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
GBGB1602413.5A 2016-02-10 2016-02-10 Method Ceased GB201602413D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1602413.5A GB201602413D0 (en) 2016-02-10 2016-02-10 Method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602413.5A GB201602413D0 (en) 2016-02-10 2016-02-10 Method
PCT/EP2017/053086 WO2017137613A1 (en) 2016-02-10 2017-02-10 Immunoassay for detection and monitoring of inflammatory responses

Publications (1)

Publication Number Publication Date
GB201602413D0 true GB201602413D0 (en) 2016-03-23

Family

ID=55642119

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1602413.5A Ceased GB201602413D0 (en) 2016-02-10 2016-02-10 Method

Country Status (2)

Country Link
GB (1) GB201602413D0 (en)
WO (1) WO2017137613A1 (en)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627D1 (en) 1990-08-29 1997-10-16 Genpharm Int Production and Nützung nonhuman transgentiere heterologous antibody production
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
AT275198T (en) 1991-12-02 2004-09-15 Medical Res Council Production of antibodies on phage surfaces from antibody segment libraries.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
SI1478667T1 (en) * 2002-02-26 2010-12-31 Sigma Tau Ind Farmaceuti Anti-human tenascin monoclonal antibody
PT1570267E (en) 2002-12-03 2012-01-03 Ucb Pharma Sa Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2009089998A1 (en) * 2008-01-15 2009-07-23 Philochem Ag Binding members for tenascin-c domain a2
BR112014014295A2 (en) 2011-12-12 2017-06-13 Isis Innovation method for determining a state of rheumatoid arthritis, kit for determining the state of erosive rheumatoid arthritis of an individual, uses of tenancin-c, and a determination of the level of tenascin-c, and methods for treating an inflammatory condition, and a rheumatoid arthritis
US20170009228A1 (en) 2014-01-13 2017-01-12 Imperial Innovations Limited Biological materials and therapeutic uses thereof
GB201414021D0 (en) 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
WO2017137613A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
GB201406151D0 (en) Method
GB201418159D0 (en) Method
GB201418469D0 (en) Method
GB201406155D0 (en) Method
GB201417712D0 (en) Method
GB201409558D0 (en) Method
GB201522399D0 (en) Process
GB2539521B (en) Process
GB201516047D0 (en) Method
GB2525464B (en) Authentication method
GB2536997B (en) Process
GB201410022D0 (en) Method
GB201503534D0 (en) Novel method
GB201502810D0 (en) Method
GB201500989D0 (en) Process
GB201522396D0 (en) Process
GB201512510D0 (en) Process
GB201507170D0 (en) Process
GB201602646D0 (en) Process
GB201414496D0 (en) Method
GB201418619D0 (en) Method
GB201417042D0 (en) Method
GB201521383D0 (en) Method
GB2527740B (en) Manufacturing method
GB2538731B (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)